Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 3
1995 1
1996 6
1997 2
1998 18
1999 26
2000 38
2001 58
2002 101
2003 122
2004 134
2005 135
2006 111
2007 141
2008 127
2009 126
2010 120
2011 140
2012 148
2013 160
2014 143
2015 165
2016 195
2017 177
2018 162
2019 132
2020 173
2021 171
2022 142
2023 121
2024 55

Text availability

Article attribute

Article type

Publication date

Search Results

2,901 results

Results by year

Filters applied: . Clear all
Page 1
Coronary In-Stent Restenosis: Predictors and Treatment.
Ullrich H, Olschewski M, Münzel T, Gori T. Ullrich H, et al. Dtsch Arztebl Int. 2021 Sep 24;118(38):637-644. doi: 10.3238/arztebl.m2021.0254. Dtsch Arztebl Int. 2021. PMID: 34379053 Free PMC article. Review.
BACKGROUND: Despite the use of modern drug-eluting stents (DES), in-stent restenosis (ISR) may still occur in as many as 2-10% of percutaneous coronary interventions (PCI) in certain lesion/patient subsets. ISR causes increased morbidity after stent implantat …
BACKGROUND: Despite the use of modern drug-eluting stents (DES), in-stent restenosis (ISR) may still occur in as many a …
Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review.
Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-Garcia HM, Waksman R. Yerasi C, et al. J Am Coll Cardiol. 2020 Mar 10;75(9):1061-1073. doi: 10.1016/j.jacc.2019.12.046. J Am Coll Cardiol. 2020. PMID: 32138967 Free article. Review.
A DCB consists of a semicompliant balloon coated with antiproliferative agents encapsulated in a polymer matrix, which is released into the wall after inflation and contact with the intima. DCB have demonstrated effectiveness in treating in-stent restenosis. …
A DCB consists of a semicompliant balloon coated with antiproliferative agents encapsulated in a polymer matrix, which is released into the …
In-stent Restenosis.
Lee MS, Banka G. Lee MS, et al. Interv Cardiol Clin. 2016 Apr;5(2):211-220. doi: 10.1016/j.iccl.2015.12.006. Epub 2016 Feb 13. Interv Cardiol Clin. 2016. PMID: 28582205 Review.
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. ...
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. ...
In-stent restenosis.
Kim MS, Dean LS. Kim MS, et al. Cardiovasc Ther. 2011 Jun;29(3):190-8. doi: 10.1111/j.1755-5922.2010.00155.x. Epub 2010 Apr 9. Cardiovasc Ther. 2011. PMID: 20406239 Free article. Review.
However, despite technological advances and an improved understanding of the restenotic process, the overall rate of in-stent restenosis following bare metal stent implantation remains high. ...The issue of in-stent restenosis (especially …
However, despite technological advances and an improved understanding of the restenotic process, the overall rate of in-stent …
Cardiac allograft vasculopathy.
Lee MS, Finch W, Weisz G, Kirtane AJ. Lee MS, et al. Rev Cardiovasc Med. 2011;12(3):143-52. Rev Cardiovasc Med. 2011. PMID: 22080925 Review.
Although revascularization with PCI has a high immediate success rate, rates of in-stent restenosis are higher as compared with PCI of native coronary arteries, although the advent of drug-eluting stents has somewhat improved in-stent resteno …
Although revascularization with PCI has a high immediate success rate, rates of in-stent restenosis are higher as compa …
Current treatment of in-stent restenosis.
Alfonso F, Byrne RA, Rivero F, Kastrati A. Alfonso F, et al. J Am Coll Cardiol. 2014 Jun 24;63(24):2659-73. doi: 10.1016/j.jacc.2014.02.545. Epub 2014 Mar 13. J Am Coll Cardiol. 2014. PMID: 24632282 Free article. Review.
Management of patients with in-stent restenosis (ISR) remains an important clinical problem. ...Intracoronary imaging provides unique insights to unravel the underlying substrate of ISR and may be used to guide repeated interventions. In this paper, we …
Management of patients with in-stent restenosis (ISR) remains an important clinical problem. ...Intracoronary im …
Drug-coated balloons: Technical and clinical progress.
Ang H, Koppara TR, Cassese S, Ng J, Joner M, Foin N. Ang H, et al. Vasc Med. 2020 Dec;25(6):577-587. doi: 10.1177/1358863X20927791. Epub 2020 Jul 7. Vasc Med. 2020. PMID: 32634046 Review.
While the current generation of drug-eluting stents (DES) are the device of choice, especially in coronary artery disease (CAD), DCB has potential applications in the treatment of de novo lesions, in-stent restenosis (ISR), bifurcations, and in peripheral art …
While the current generation of drug-eluting stents (DES) are the device of choice, especially in coronary artery disease (CAD), DCB has pot …
In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial).
Xenogiannis I, Rangan BV, Uyeda L, Banerjee S, Edson R, Bhatt DL, Goldman S, Holmes DR Jr, Rao SV, Shunk K, Mavromatis K, Ramanathan K, Bavry AA, McFalls EO, Garcia S, Thai H, Uretsky BF, Latif F, Armstrong E, Ortiz J, Jneid H, Liu J, Aggrawal K, Conner TA, Wagner T, Karacsonyi J, Ventura B, Alsleben A, Lu Y, Shih MC, Brilakis ES. Xenogiannis I, et al. Am J Cardiol. 2022 Jan 1;162:24-30. doi: 10.1016/j.amjcard.2021.09.024. Epub 2021 Nov 1. Am J Cardiol. 2022. PMID: 34736721 Clinical Trial.
Saphenous vein grafts (SVGs) have high rates of in-stent restenosis (ISR). We compared the baseline clinical and angiographic characteristics of patients and lesions that did develop ISR with those who did not develop ISR during a median follow-up of 2 …
Saphenous vein grafts (SVGs) have high rates of in-stent restenosis (ISR). We compared the baseline clinical and …
Waksman In-Stent Restenosis Classification: A Mechanism-Based Approach to the Treatment of Restenosis.
Shlofmitz E, Case BC, Chen Y, Chezar-Azerrad C, Hashim H, Garcia-Garcia HM, Mintz GS, Waksman R. Shlofmitz E, et al. Cardiovasc Revasc Med. 2021 Dec;33:62-67. doi: 10.1016/j.carrev.2021.06.004. Epub 2021 Jun 5. Cardiovasc Revasc Med. 2021. PMID: 34247983 Review.
Despite contemporary advances in stent technology, in-stent restenosis (ISR) remains a common issue following percutaneous coronary intervention. ...Intravascular imaging with either intravascular ultrasound or optical coherence tomography allows for real-tim …
Despite contemporary advances in stent technology, in-stent restenosis (ISR) remains a common issue following percutane …
A Randomized Comparison of 2 Different Drug-Coated Balloons for In-Stent Restenosis.
Liu S, Zhou Y, Shen Z, Chen H, Qiu C, Fu G, Li H, Yu Z, Zeng Q, Li Z, Li W, Qiao S; Dissolve ISR Investigators. Liu S, et al. JACC Cardiovasc Interv. 2023 Apr 10;16(7):759-767. doi: 10.1016/j.jcin.2022.12.018. JACC Cardiovasc Interv. 2023. PMID: 37045496 Free article. Clinical Trial.
BACKGROUND: Although use of drug-coated balloons (DCB) is a promising technique, little is known about the clinical efficacy of the Dissolve DCB in drug-eluting stent (DES) in-stent restenosis (ISR). ...However, Dissolve DCB with its numerical increase …
BACKGROUND: Although use of drug-coated balloons (DCB) is a promising technique, little is known about the clinical efficacy of the D …
2,901 results